WO2002036161A3 - Novel targeted compositions for diagnostic and therapeutic use - Google Patents

Novel targeted compositions for diagnostic and therapeutic use Download PDF

Info

Publication number
WO2002036161A3
WO2002036161A3 PCT/US2001/032308 US0132308W WO0236161A3 WO 2002036161 A3 WO2002036161 A3 WO 2002036161A3 US 0132308 W US0132308 W US 0132308W WO 0236161 A3 WO0236161 A3 WO 0236161A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
compositions
diagnostic
therapeutic use
therapeutic
Prior art date
Application number
PCT/US2001/032308
Other languages
French (fr)
Other versions
WO2002036161A2 (en
Inventor
Evan C Unger
Terry O Matsunaga
Patricia A Schumann
Original Assignee
Imarx Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imarx Therapeutics Inc filed Critical Imarx Therapeutics Inc
Priority to AU1328502A priority Critical patent/AU1328502A/en
Priority to AU2002213285A priority patent/AU2002213285B2/en
Priority to EP01981655A priority patent/EP1365805A2/en
Priority to CA002428606A priority patent/CA2428606A1/en
Priority to JP2002538970A priority patent/JP2005500245A/en
Publication of WO2002036161A2 publication Critical patent/WO2002036161A2/en
Publication of WO2002036161A3 publication Critical patent/WO2002036161A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/227—Liposomes, lipoprotein vesicles, e.g. LDL or HDL lipoproteins, micelles, e.g. phospholipidic or polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Novel targeted compositions which may be used for diagnostic and therapeutic use. The compositions may comprise lipid, protein or polymer gas-filled vesicles which further comprise novel compounds of the general formula L-P-T, wherein L comprises a hydrophobic compound, P comprises a hydrophilic polymer, and T comprises a targeting ligand which targets tissues, cells or receptors, including myocardial cells, endothelial cells, epithelial cells, tumor cells and the glycoprotein GPIIbIIIa receptor. The compositions can be used in conjunction with diagnostic imaging, such as ultrasound, as well as therapeutic applications, such as therapeutic ultrasound.
PCT/US2001/032308 2000-10-30 2001-10-17 Novel targeted compositions for diagnostic and therapeutic use WO2002036161A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU1328502A AU1328502A (en) 2000-10-30 2001-10-17 Novel targeted compositions for diagnostic and therapeutic use
AU2002213285A AU2002213285B2 (en) 2000-10-30 2001-10-17 Novel targeted compositions for diagnostic and therapeutic use
EP01981655A EP1365805A2 (en) 2000-10-30 2001-10-17 Novel targeted compositions for diagnostic and therapeutic use
CA002428606A CA2428606A1 (en) 2000-10-30 2001-10-17 Novel targeted compositions for diagnostic and therapeutic use
JP2002538970A JP2005500245A (en) 2000-10-30 2001-10-17 Novel targeted compositions for use in diagnosis and therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/699,679 US7452551B1 (en) 2000-10-30 2000-10-30 Targeted compositions for diagnostic and therapeutic use
US09/699,679 2000-10-30

Publications (2)

Publication Number Publication Date
WO2002036161A2 WO2002036161A2 (en) 2002-05-10
WO2002036161A3 true WO2002036161A3 (en) 2003-09-25

Family

ID=24810416

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/032308 WO2002036161A2 (en) 2000-10-30 2001-10-17 Novel targeted compositions for diagnostic and therapeutic use

Country Status (6)

Country Link
US (1) US7452551B1 (en)
EP (1) EP1365805A2 (en)
JP (1) JP2005500245A (en)
AU (2) AU2002213285B2 (en)
CA (1) CA2428606A1 (en)
WO (1) WO2002036161A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8835556B2 (en) 2002-12-31 2014-09-16 Nektar Therapeutics Hydrolytically stable maleimide-terminated polymers

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0129121D0 (en) * 2001-12-05 2002-01-23 Ic Vec Ltd Compound
US20080009561A1 (en) * 2004-09-03 2008-01-10 Imarx Therapeutics, Inc. Apparatus And Method To Prepare A Microsphere-Forming Composition
US7815575B2 (en) * 2005-05-09 2010-10-19 Salutron, Inc. Ultrasonic monitor with a biocompatible oil based transmission medium
JP2008220868A (en) * 2007-03-15 2008-09-25 Ge Medical Systems Global Technology Co Llc Contrast medium and magnetic resonance imaging equipment
US8580230B2 (en) * 2009-02-23 2013-11-12 Kent State University Materials and methods for MRI contrast agents and drug delivery
US11096901B2 (en) 2009-03-06 2021-08-24 Metaqor Llc Dynamic bio-nanoparticle platforms
US11235062B2 (en) * 2009-03-06 2022-02-01 Metaqor Llc Dynamic bio-nanoparticle elements
CA2934401C (en) 2009-11-02 2017-01-10 Pulse Therapeutics, Inc. Magnetomotive stator system and methods for wireless control of magnetic rotors
EP2407157A1 (en) * 2010-07-13 2012-01-18 Koninklijke Philips Electronics N.V. Lipid bilayer carrier for drugs or imaging agents
US10357575B2 (en) 2010-09-24 2019-07-23 Case Western Reserve University Stabilized nanobubbles for diagnostic and therapeutic applications
WO2013050529A2 (en) 2011-10-06 2013-04-11 European Molecular Biology Laboratory Use of igf-1 in the modulation of treg cell activity and the treatment and prevention of autoimmune disorders or diseases
WO2013173235A1 (en) * 2012-05-15 2013-11-21 Pulse Therapeutics, Inc. Magnetic-based systems and methods for manipulation of magnetic particles
US10881310B2 (en) 2012-08-25 2021-01-05 The Board Of Trustees Of The Leland Stanford Junior University Motion artifact mitigation methods and devices for pulse photoplethysmography
US10035009B2 (en) 2013-04-15 2018-07-31 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for treating pancreatic cancer
US10434194B2 (en) 2013-06-20 2019-10-08 Case Western Reserve University PSMA targeted nanobubbles for diagnostic and therapeutic applications
RU2685869C1 (en) * 2014-08-22 2019-04-23 Нэшенл Ченг Кунг Юниверсити Versions of disintegrin and their pharmaceutical application
EP3310261A4 (en) 2015-06-19 2019-01-23 Neural Analytics, Inc. Transcranial doppler probe
US10617388B2 (en) 2016-01-05 2020-04-14 Neural Analytics, Inc. Integrated probe structure
US11589836B2 (en) 2016-01-05 2023-02-28 Novasignal Corp. Systems and methods for detecting neurological conditions
CN108778140A (en) 2016-01-05 2018-11-09 神经系统分析公司 System and method for determining clinical indication
US11918315B2 (en) 2018-05-03 2024-03-05 Pulse Therapeutics, Inc. Determination of structure and traversal of occlusions using magnetic particles
US11813358B2 (en) 2019-06-07 2023-11-14 Regents Of The University Of Michigan Lipid nanodisc formation by polymers having a pendant hydrophobic group
CA3146607A1 (en) 2019-09-01 2021-03-04 Joseph Yeshayahu KLEIN Cannabinoid containing targeting liposomes
CN110946992B (en) * 2019-12-02 2022-08-02 深圳大学 Preparation method and application of cationic microbubble
CN112550422B (en) * 2021-01-15 2022-08-09 义乌市旻具五金工具有限公司 Ice and snow road surface commodity circulation travelling bogie
WO2023094987A1 (en) * 2021-11-23 2023-06-01 Ghamkhari Aliyeh A drug delivery composition for treating myocardial infraction (mi)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040285A1 (en) * 1995-06-07 1996-12-19 Imarx Pharmaceutical Corp. Novel targeted compositions for diagnostic and therapeutic use
WO1999013919A1 (en) * 1997-09-17 1999-03-25 Imarx Pharmaceutical Corp. Novel targeted contrast agents for diagnostic and therapeutic use
WO2000045856A2 (en) * 1999-02-03 2000-08-10 Imarx Pharmaceutical Corp. Novel methods of imaging and treatment with targeted compositions

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3015128A (en) 1960-08-18 1962-01-02 Southwest Res Inst Encapsulating apparatus
US3291843A (en) 1963-10-08 1966-12-13 Du Pont Fluorinated vinyl ethers and their preparation
BE661981A (en) 1964-04-03
US3594326A (en) 1964-12-03 1971-07-20 Ncr Co Method of making microscopic capsules
US3968203A (en) 1965-10-01 1976-07-06 Jerome G. Spitzer Aerosol astringent composition
US3401475A (en) 1966-07-18 1968-09-17 Dow Chemical Co Label and labelled container
US3488714A (en) 1966-09-19 1970-01-06 Dow Chemical Co Formed laminate structure and method of preparation
US3615972A (en) 1967-04-28 1971-10-26 Dow Chemical Co Expansible thermoplastic polymer particles containing volatile fluid foaming agent and method of foaming the same
US3532500A (en) 1967-07-25 1970-10-06 Eastman Kodak Co Light sensitive vesicular composition comprising an azido-s-triazine compound
US3557294A (en) 1967-10-12 1971-01-19 Allied Chem Fluorinated ethers as inhalation convulsants
US3479811A (en) 1967-11-29 1969-11-25 Dow Chemical Co Yarn and method of making the same
US3732172A (en) 1968-02-28 1973-05-08 Ncr Co Process for making minute capsules and prefabricated system useful therein
US3650831A (en) 1969-03-10 1972-03-21 Armour Dial Inc Method of cleaning surfaces
US4027007A (en) 1970-12-09 1977-05-31 Colgate-Palmolive Company Antiperspirants formulated with borax
US3873564A (en) 1971-03-03 1975-03-25 Synvar Ass 2-Imidazolinyl-3-oxide-1-oxypropionic acid
US4108806A (en) 1971-12-06 1978-08-22 The Dow Chemical Company Thermoplastic expandable microsphere process and product
US4179546A (en) 1972-08-28 1979-12-18 The Dow Chemical Company Method for expanding microspheres and expandable composition
US3960583A (en) 1974-05-02 1976-06-01 Philadelphia Quartz Company Method of preparing modified hollow, largely spherical particles by spray drying
CH588887A5 (en) 1974-07-19 1977-06-15 Battelle Memorial Institute
US3945956A (en) 1975-06-23 1976-03-23 The Dow Chemical Company Polymerization of styrene acrylonitrile expandable microspheres
US4138383A (en) 1975-11-24 1979-02-06 California Institute Of Technology Preparation of small bio-compatible microspheres
GB1523965A (en) 1976-03-19 1978-09-06 Ici Ltd Pharmaceutical compositions containing steroids
US4162282A (en) 1976-04-22 1979-07-24 Coulter Electronics, Inc. Method for producing uniform particles
GB1599881A (en) 1977-02-02 1981-10-07 Millington A R Preparation for diagnostic radiology
CH621479A5 (en) 1977-08-05 1981-02-13 Battelle Memorial Institute
CH624011A5 (en) 1977-08-05 1981-07-15 Battelle Memorial Institute
US4192859A (en) 1978-09-29 1980-03-11 E. R. Squibb & Sons, Inc. Contrast media containing liposomes as carriers
US4310506A (en) 1979-02-22 1982-01-12 California Institute Of Technology Means of preparation and applications of liposomes containing high concentrations of entrapped ionic species
US4276885A (en) 1979-05-04 1981-07-07 Rasor Associates, Inc Ultrasonic image enhancement
US4265251A (en) 1979-06-28 1981-05-05 Rasor Associates, Inc. Method of determining pressure within liquid containing vessel
US4303736A (en) 1979-07-20 1981-12-01 Leonard Torobin Hollow plastic microspheres
US4310505A (en) 1979-11-08 1982-01-12 California Institute Of Technology Lipid vesicles bearing carbohydrate surfaces as lymphatic directed vehicles for therapeutic and diagnostic substances
US4342826A (en) 1980-02-04 1982-08-03 Collaborative Research, Inc. Immunoassay products and methods
US4421562A (en) 1980-04-13 1983-12-20 Pq Corporation Manufacturing process for hollow microspheres
US4344929A (en) 1980-04-25 1982-08-17 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4315514A (en) 1980-05-08 1982-02-16 William Drewes Method and apparatus for selective cell destruction
US4331654A (en) 1980-06-13 1982-05-25 Eli Lilly And Company Magnetically-localizable, biodegradable lipid microspheres
US4657756A (en) 1980-11-17 1987-04-14 Schering Aktiengesellschaft Microbubble precursors and apparatus for their production and use
US4681119A (en) 1980-11-17 1987-07-21 Schering Aktiengesellschaft Method of production and use of microbubble precursors
US4442843A (en) 1980-11-17 1984-04-17 Schering, Ag Microbubble precursors and methods for their production and use
US4420442A (en) 1981-04-13 1983-12-13 Pq Corporation Manufacturing process for hollow microspheres
US4533254A (en) 1981-04-17 1985-08-06 Biotechnology Development Corporation Apparatus for forming emulsions
EP0068961A3 (en) 1981-06-26 1983-02-02 Thomson-Csf Apparatus for the local heating of biological tissue
US4534899A (en) 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4426330A (en) 1981-07-20 1984-01-17 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4569836A (en) 1981-08-27 1986-02-11 Gordon Robert T Cancer treatment by intracellular hyperthermia
DE3141641A1 (en) 1981-10-16 1983-04-28 Schering Ag, 1000 Berlin Und 4619 Bergkamen ULTRASONIC CONTRAST AGENTS AND THEIR PRODUCTION
BR8107560A (en) 1981-11-19 1983-07-05 Luiz Romariz Duarte ULTRASONIC STIMULATION OF BONE FRACTURE CONSOLIDATION
US4540629A (en) 1982-04-08 1985-09-10 Pq Corporation Hollow microspheres with organosilicon-silicate walls
DE3225848A1 (en) 1982-07-07 1984-01-19 Schering AG, 1000 Berlin und 4709 Bergkamen PREPARATION OF CORTICOIDS FOR TOPICAL APPLICATION
JPS58501576A (en) 1982-09-22 1983-09-22 エム．ビイ−．フイラ−ズ　プテイ．リミテツド Material, hollow bilayer silicate microspheres
FR2534487B1 (en) 1982-10-15 1988-06-10 Dior Christian Parfums METHOD FOR THE HOMOGENEIZATION OF HYDRATED LIPIDAL LAMELLAR PHASE DISPERSIONS, AND SUSPENSIONS OBTAINED THEREBY
EP0111386B1 (en) 1982-10-26 1987-11-19 University Of Aberdeen Ultrasound hyperthermia unit
US4603044A (en) 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
US4731239A (en) 1983-01-10 1988-03-15 Gordon Robert T Method for enhancing NMR imaging; and diagnostic use
US4572203A (en) 1983-01-27 1986-02-25 Feinstein Steven B Contact agents for ultrasonic imaging
US4718433A (en) 1983-01-27 1988-01-12 Feinstein Steven B Contrast agents for ultrasonic imaging
US4775522A (en) 1983-03-04 1988-10-04 Children's Hospital Research Foundation, A Division Of Children's Hospital Medical Center NMR compositions for indirectly detecting a dissolved gas in an animal
US4981692A (en) 1983-03-24 1991-01-01 The Liposome Company, Inc. Therapeutic treatment by intramammary infusion
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4900540A (en) 1983-06-20 1990-02-13 Trustees Of The University Of Massachusetts Lipisomes containing gas for ultrasound detection
JPS6019033A (en) 1983-07-12 1985-01-31 Matsumoto Yushi Seiyaku Kk Hollow micro-balloon and preparation thereof
US4615879A (en) 1983-11-14 1986-10-07 Vanderbilt University Particulate NMR contrast agents for gastrointestinal application
FR2563725B1 (en) 1984-05-03 1988-07-15 Dory Jacques APPARATUS FOR EXAMINING AND LOCATING ULTRASONIC TUMORS WITH A LOCALIZED HYPERTHERMAL TREATMENT DEVICE
GB8407557D0 (en) 1984-03-23 1984-05-02 Hayward J A Polymeric lipsomes
FR2562421B1 (en) 1984-04-09 1989-02-17 Sandoz Sa IMPROVEMENTS ON INTERLEUKIN THERAPY
US4728575A (en) 1984-04-27 1988-03-01 Vestar, Inc. Contrast agents for NMR imaging
US4620546A (en) 1984-06-30 1986-11-04 Kabushiki Kaisha Toshiba Ultrasound hyperthermia apparatus
SE8403905D0 (en) 1984-07-30 1984-07-30 Draco Ab LIPOSOMES AND STEROID ESTERS
US4767610A (en) 1984-10-19 1988-08-30 The Regents Of The University Of California Method for detecting abnormal cell masses in animals
US4789501A (en) 1984-11-19 1988-12-06 The Curators Of The University Of Missouri Glass microspheres
US4921706A (en) 1984-11-20 1990-05-01 Massachusetts Institute Of Technology Unilamellar lipid vesicles and method for their formation
US4830858A (en) 1985-02-11 1989-05-16 E. R. Squibb & Sons, Inc. Spray-drying method for preparing liposomes and products produced thereby
US4689986A (en) 1985-03-13 1987-09-01 The University Of Michigan Variable frequency gas-bubble-manipulating apparatus and method
US4663161A (en) 1985-04-22 1987-05-05 Mannino Raphael J Liposome methods and compositions
JPS63500175A (en) 1985-05-22 1988-01-21 リポソ−ム　テクノロジ−，インコ−ポレイテツド Liposome inhalation method and inhalation system
US4684479A (en) 1985-08-14 1987-08-04 Arrigo Joseph S D Surfactant mixtures, stable gas-in-liquid emulsions, and methods for the production of such emulsions from said mixtures
US4938947A (en) 1985-11-01 1990-07-03 Centre National De La Recherche Scientifique (Cnrs) Aerosol composition for in vivo imaging
US4865836A (en) 1986-01-14 1989-09-12 Fluoromed Pharmaceutical, Inc. Brominated perfluorocarbon emulsions for internal animal use for contrast enhancement and oxygen transport
US4927623A (en) 1986-01-14 1990-05-22 Alliance Pharmaceutical Corp. Dissolution of gas in a fluorocarbon liquid
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4834964A (en) 1986-03-07 1989-05-30 M.R.I., Inc. Use of charged nitroxides as NMR image enhancing agents for CSF
JPH0751496B2 (en) 1986-04-02 1995-06-05 武田薬品工業株式会社 Manufacturing method of liposome
US4728578A (en) 1986-08-13 1988-03-01 The Lubrizol Corporation Compositions containing basic metal salts and/or non-Newtonian colloidal disperse systems and vinyl aromatic containing polymers
US4776991A (en) 1986-08-29 1988-10-11 The United States Of America As Represented By The Secretary Of The Navy Scaled-up production of liposome-encapsulated hemoglobin
US4781871A (en) 1986-09-18 1988-11-01 Liposome Technology, Inc. High-concentration liposome processing method
US4769241A (en) 1986-09-23 1988-09-06 Alpha Therapeutic Corporation Apparatus and process for oxygenation of liquid state dissolved oxygen-carrying formulation
ZW11287A1 (en) 1986-11-04 1989-01-25 Aeci Ltd Process for the production of an explosive
US4863717A (en) 1986-11-10 1989-09-05 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon Methods for circumventing the problem of free radial reduction associated with the use of stable nitroxide free radicals as contrast agents for magnetic reasonance imaging
US4933121A (en) 1986-12-10 1990-06-12 Ciba Corning Diagnostics Corp. Process for forming liposomes
CA1321048C (en) 1987-03-05 1993-08-10 Robert W. J. Lencki Microspheres and method of producing same
US4866096A (en) 1987-03-20 1989-09-12 Air Products And Chemicals, Inc. Stable fluorochemical aqueous emulsions
US4895876A (en) 1987-03-20 1990-01-23 Air Products And Chemicals, Inc. Concentrated stable fluorochemical aqueous emulsions containing triglycerides
US4844882A (en) 1987-12-29 1989-07-04 Molecular Biosystems, Inc. Concentrated stabilized microbubble-type ultrasonic imaging agent
US4898734A (en) 1988-02-29 1990-02-06 Massachusetts Institute Of Technology Polymer composite for controlled release or membrane formation
US4893624A (en) 1988-06-21 1990-01-16 Massachusetts Institute Of Technology Diffuse focus ultrasound hyperthermia system
DE3824354A1 (en) 1988-07-19 1990-01-25 Basf Ag METHOD FOR THE PRODUCTION OF CELL-CONTAINING PLASTICS BY THE POLYISOCYANATE-POLYADDITION PROCESS BY MEANS OF STORAGE-STABLE, FUEL-CONTAINING EMULSIONS AND THESE EMULSIONS
US4957656A (en) 1988-09-14 1990-09-18 Molecular Biosystems, Inc. Continuous sonication method for preparing protein encapsulated microbubbles
US5536814A (en) * 1993-09-27 1996-07-16 La Jolla Cancer Research Foundation Integrin-binding peptides
US6113570A (en) * 1994-09-09 2000-09-05 Coraje, Inc. Method of removing thrombosis in fistulae

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040285A1 (en) * 1995-06-07 1996-12-19 Imarx Pharmaceutical Corp. Novel targeted compositions for diagnostic and therapeutic use
WO1999013919A1 (en) * 1997-09-17 1999-03-25 Imarx Pharmaceutical Corp. Novel targeted contrast agents for diagnostic and therapeutic use
WO2000045856A2 (en) * 1999-02-03 2000-08-10 Imarx Pharmaceutical Corp. Novel methods of imaging and treatment with targeted compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SUCHKOVA VALENTINA N ET AL: "Enhancement of ultrasound-mediated fibrinolysis by platelet-targeted microbubble contrast agents.", BLOOD, vol. 98, no. 11 Part 1, 16 November 2001 (2001-11-16), 43rd Annual Meeting of the American Society of Hematology, Part 1;Orlando, Florida, USA; December 07-11, 2001, November 16, 2001, pages 43a, XP001109599, ISSN: 0006-4971 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8835556B2 (en) 2002-12-31 2014-09-16 Nektar Therapeutics Hydrolytically stable maleimide-terminated polymers

Also Published As

Publication number Publication date
AU2002213285B2 (en) 2006-12-21
CA2428606A1 (en) 2002-05-10
WO2002036161A2 (en) 2002-05-10
US7452551B1 (en) 2008-11-18
AU1328502A (en) 2002-05-15
JP2005500245A (en) 2005-01-06
EP1365805A2 (en) 2003-12-03

Similar Documents

Publication Publication Date Title
WO2002036161A3 (en) Novel targeted compositions for diagnostic and therapeutic use
EP0831932A4 (en) Novel targeted compositions for diagnostic and therapeutic use
WO2000045856A3 (en) Novel methods of imaging and treatment with targeted compositions
CA2406650A1 (en) Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites
WO2001008712A3 (en) Targeting multimeric imaging agents through multilocus binding
HK1027979A1 (en) Indole derivatives and their use as mcp-1 antagonists
EP2279757A3 (en) Compounds for targeting endothelial cells
WO2002100336A3 (en) Tissue-specific endothelial membrane proteins
EP3118218A3 (en) Fusion proteins for blood-brain barrier delivery
WO2006044660A3 (en) Functionalized solid lipid nanoparticles and methods of making and using same
MXPA05010118A (en) Heterobifunctional polymeric bioconjugates.
WO2007067979A3 (en) Targeting vector-phospholipid conjugates
BR9809100A (en) Combinations of fungicidal active substances
WO2006007712A8 (en) Methods comprising polyethylene glycol-lipid conjugates for delivery of therapeutic agents
EP2147679A3 (en) Compositions and methods for modulating blood-brain barrier transport
WO2005097202A3 (en) Use of serum albumin binding peptides conjugates for the preparation of a medicament
IE902139L (en) Imidazolyl alkenoic acids
WO2002057261A3 (en) Diaminothiazoles and their use as inhibitors of cyclin-dependent kinase
CA2408535A1 (en) Compositions comprising dendrimer complexes
WO2003061593A3 (en) Novel targeted compositions for diagnostic and therapeutic use
EP1992695A3 (en) C-type lectin transmembrane antigen expressed in human prostate cancer and uses thereof
WO2003084470A3 (en) Compositions and methods for targeted biological delivery of molecular carriers
WO2001077145A3 (en) Integrin binding peptide derivatives
EP0997472A3 (en) Spirocyclic C-glycosides
NO971341D0 (en) Promoter for receptor tyrosine kinase TIE

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002538970

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2428606

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001981655

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002213285

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2001981655

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001981655

Country of ref document: EP